Every entry on PeptideWikis, alphabetically — 45 entries. Each one gives what the peptide is, what the research found by evidence level, the regulatory status (FDA, compounding category, WADA) and the side effects reported, with every claim cited to a primary source. Updated 2026-10-28.
Terms such as 503A, WADA S0 or half-life are defined in the peptide glossary.
0–9 · A · B · C · D · E · G · I · K · L · M · N · O · P · R · S · T · W
0–9
- 5-Amino-1MQ (NNMT inhibitor): mouse studies, unknown safety and legal status
- 503A vs 503B peptides: what each compounding pathway may do
A
B
C
- CagriSema (cagrilintide + semaglutide): phase 3 results, side effects and FDA status
- Category 1 vs Category 2 peptides: what FDA’s 503A compounding lists mean
- Cerebrolysin: benefits, evidence and legal status
- CJC-1295 with and without DAC (Mod GRF 1-29): how they differ, studies and FDA votes
D
- Dihexa: benefits, evidence and legal status
- Do peptides cause cancer? The evidence for GLP-1 drugs, growth hormone peptides, BPC-157 and TB-500
- DSIP (emideltide): sleep and withdrawal studies, FDA review and legal status
E
G
- GHK-Cu and cancer: what lab, animal and gene studies show
- GHK-Cu copper peptide: topical vs injected use, evidence and FDA status
- GHRP-2 and GHRP-6: benefits, evidence and legal status
I
- IGF-1 LR3: benefits, evidence and legal status
- Ipamorelin: growth hormone studies, the bowel-surgery trial, FDA vote and WADA ban
K
- Kisspeptin (kisspeptin-10, kisspeptin-54, metastin): what it is, evidence and legal status
- KPV peptide (Lys-Pro-Val): lab and animal evidence, FDA review and WADA status
L
M
- Mazdutide: benefits, evidence and legal status
- MOTS-c (mitochondrial peptide): mouse studies, FDA review and WADA ban
N
O
P
- Peptide legal status tracker 2026: FDA, compounding and WADA status by peptide
- Pharmacy Compounding Advisory Committee and peptides: the July 2026 votes and the February 2027 meeting
- Pinealon: benefits, evidence and legal status
- PT-141 (bremelanotide): benefits, evidence and legal status
R
- Research use only peptides: what the label means legally and why it matters
- Retatrutide (LY3437943): phase 3 trial results, side effects and legal status
- Retatrutide FDA approval timeline: trial readouts, BLA filing and decision window
S
- Selank (TP-7): anxiety studies, Russian registration and legal status
- Semax: benefits, evidence and legal status
- Sermorelin: benefits, evidence and legal status
- SLU-PP-332 (not a peptide): benefits, evidence and legal status
- SS-31 (elamipretide): benefits, evidence and legal status
- Survodutide: benefits, evidence and legal status
T
- TB-500 vs thymosin beta-4: what is known about the fragment and the full protein
- Teriparatide (Forteo): benefits, evidence and legal status
- Tesamorelin (Egrifta): benefits, evidence and legal status
- The FDA’s July 2026 peptide vote: what it means for BPC-157 and TB-500
- Thymosin alpha-1 (thymalfasin, Zadaxin): trials, the FDA vote and legal status